OBJECTIVE: Transcatheter aortic valve implantation (TAVI) is a therapeutic option for old and multimorbid patients with severe aortic stenosis. When applying the groin first approach by transfemoral implantation, patients in the transapical group are highly selected with even higher morbidity. We report outcome of the transapical group. METHODS: Between April 2008 and May 2011, 267 patients underwent TAVI through either a transfemoral (n = 201 CoreValve, n = 33 Edwards Sapien prostheses; mean age 81 ± 6 years, logistic EuroSCORE 19.5 ± 12.6 %; 4-76, STS score 7.2 ± 4 %; 1.5-28.9) or transapical approach (n = 33 Edwards Sapien prostheses; mean age 80 ± 1 years, logistic EuroSCORE 31.6 ± 17.1 %; 9.4-69.1, STS score 12.8 ± 7.1 %; 2.5-28.8). The transapical access was chosen only when transfemoral implantation was not possible. RESULTS: EuroSCORE and STS score were significantly higher in the transapical group (p = 0.001, respectively). A 30-day survival was comparable with 87.9 % in the transapical versus 92 % in the transfemoral group (p = 0.52). In the transapical group, female gender was predominant (n = 23; 70 %). Eight patients underwent previous cardiac surgery. All transapical implantations were successful. No bleeding or neurological complications occurred. Six patients required postoperative pacemaker implantation. Cardiac decompensation with concomitant pneumonia was the underlying cause for early mortality, except for one patient with abdominal malperfusion. Follow-up (0-37 months) was complete in 100 %, nine patients died after 30 days postoperatively (6 cardiac and 3 non-cardiac related). Echocardiography revealed good valve function with not more than mild paravalvular incompetence. CONCLUSIONS: Groin first approach is reasonable due to less invasive implantation technique. However, despite even higher predicted mortality, transapical aortic valve implantation is non-inferior to transfemoral approach.
OBJECTIVE:Transcatheter aortic valve implantation (TAVI) is a therapeutic option for old and multimorbid patients with severe aortic stenosis. When applying the groin first approach by transfemoral implantation, patients in the transapical group are highly selected with even higher morbidity. We report outcome of the transapical group. METHODS: Between April 2008 and May 2011, 267 patients underwent TAVI through either a transfemoral (n = 201 CoreValve, n = 33 Edwards Sapien prostheses; mean age 81 ± 6 years, logistic EuroSCORE 19.5 ± 12.6 %; 4-76, STS score 7.2 ± 4 %; 1.5-28.9) or transapical approach (n = 33 Edwards Sapien prostheses; mean age 80 ± 1 years, logistic EuroSCORE 31.6 ± 17.1 %; 9.4-69.1, STS score 12.8 ± 7.1 %; 2.5-28.8). The transapical access was chosen only when transfemoral implantation was not possible. RESULTS: EuroSCORE and STS score were significantly higher in the transapical group (p = 0.001, respectively). A 30-day survival was comparable with 87.9 % in the transapical versus 92 % in the transfemoral group (p = 0.52). In the transapical group, female gender was predominant (n = 23; 70 %). Eight patients underwent previous cardiac surgery. All transapical implantations were successful. No bleeding or neurological complications occurred. Six patients required postoperative pacemaker implantation. Cardiac decompensation with concomitant pneumonia was the underlying cause for early mortality, except for one patient with abdominal malperfusion. Follow-up (0-37 months) was complete in 100 %, nine patients died after 30 days postoperatively (6 cardiac and 3 non-cardiac related). Echocardiography revealed good valve function with not more than mild paravalvular incompetence. CONCLUSIONS: Groin first approach is reasonable due to less invasive implantation technique. However, despite even higher predicted mortality, transapical aortic valve implantation is non-inferior to transfemoral approach.
Authors: Thomas Walther; Volkmar Falk; Michael A Borger; Todd Dewey; Gerhard Wimmer-Greinecker; Gerhard Schuler; Michael Mack; Friedrich W Mohr Journal: Eur J Cardiothorac Surg Date: 2006-11-09 Impact factor: 4.191
Authors: Thomas Walther; Volkmar Falk; Jörg Kempfert; Michael A Borger; Jens Fassl; Michael W A Chu; Gerhard Schuler; Friedrich W Mohr Journal: Eur J Cardiothorac Surg Date: 2008-02-21 Impact factor: 4.191
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Samuel V Lichtenstein; Anson Cheung; Jian Ye; Christopher R Thompson; Ronald G Carere; Sanjeevan Pasupati; John G Webb Journal: Circulation Date: 2006-07-31 Impact factor: 29.690
Authors: Jörg Kempfert; Ardawan Rastan; David Holzhey; Axel Linke; Gerhard Schuler; Arnaud van Linden; Johannes Blumenstein; Friedrich Wilhelm Mohr; Thomas Walther Journal: Circulation Date: 2011-09-13 Impact factor: 29.690
Authors: Alexander Sedaghat; Jan-Malte Sinning; Mariuca Vasa-Nicotera; Alexander Ghanem; Christoph Hammerstingl; Eberhard Grube; Georg Nickenig; Nikos Werner Journal: Clin Res Cardiol Date: 2013-07-23 Impact factor: 5.460
Authors: Marcel Weber; Eva Brüggemann; Robert Schueler; Diana Momcilovic; Jan-Malte Sinning; Alexander Ghanem; Nikos Werner; Eberhard Grube; Wolfgang Schiller; Fritz Mellert; Armin Welz; Georg Nickenig; Christoph Hammerstingl Journal: Clin Res Cardiol Date: 2015-05-13 Impact factor: 5.460
Authors: Zisis Dimitriadis; Marcus Wiemer; Werner Scholtz; Lothar Faber; Cornelia Piper; Thomas Bitter; Ippokratis Messaritakis; Kevin Bullert; Jochen Boergermann; Georg Kleikamp; Christian Prinz; Dieter Horstkotte; Olaf Oldenburg Journal: Clin Res Cardiol Date: 2013-08-21 Impact factor: 5.460
Authors: Nicolas A Geis; Emmanuel Chorianopoulos; Klaus Kallenbach; Florian André; Sven T Pleger; Matthias Karck; Hugo A Katus; Raffi Bekeredjian Journal: Clin Res Cardiol Date: 2014-04-21 Impact factor: 5.460